Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1972 Jan;51(1):45–49. doi: 10.1172/JCI106795

Concentrations of Idoxuridine in Serum, Urine, and Cerebrospinal Fluid of Patients with Suspected Diagnoses of Herpesvirus hominis Encephalitis

A Martin Lerner 1, Elizabeth Jane Bailey 1
PMCID: PMC332927  PMID: 4331799

Abstract

A reproducible microbiologic assay of microgram quantities of idoxuridine (IDU) in serum, urine, or cerebrospinal fluid is presented. The antiviral assay is not interfered with by type-specific antibody or interferon. During slow intravenous infusions of idox-uridine (4 mg/min) in patients with suspected diagnoses of Herpesvirus hominis encephalitis, the rate of inactivation and/or removal of drug exceeded its administration. During several rapid infusions of idoxuridine (50 mg/min) significant quantities of the drug were found in serum, urine, and cerebrospinal fluid. Idoxuridine is not significantly bound to serum proteins and is not deiodinated in fresh serum or urine in vitro to inactive products (iodouracil, uracil, iodide). It is rapidly excreted into the urine. Inactivation of IDU occurs in tissues. This antiviral assay of IDU in body fluids should be applicable to other viruses and potential antiviral agents.

Minimal inhibitory concentrations of IDU for fresh isolates of Herpesvirus hominis (type 1 or 2) were determined. Type 1 herpesviruses' microplaques in baby hamster kidney cell (BHK 21) tissue cultures were sensitive to 2.5-10 μg/0.4 ml. Type 2 macroplaques required 25-50 μg/0.4 ml. This latter characteristic may be an additional biologic marker which may be useful in suggesting type-specificity of herpesvirus isolates.

Full text

PDF
45

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CALABRESI P., CARDOSO S. S., FINCH S. C., KLIGERMAN M. M., VON ESSEN C. F., CHU M. Y., WELCH A. D. Initial clinical studies with 5-iodo-2'-deoxyuridine. Cancer Res. 1961 May;21:550–559. [PubMed] [Google Scholar]
  2. Clarkson D. R., Oppelt W. W., Byvoet P. The fate of 5-iodo-2'-deoxyuridine (IUdR) in plasma and cerebrospinal fluid of dogs. J Pharmacol Exp Ther. 1967 Sep;157(3):581–588. [PubMed] [Google Scholar]
  3. Dowdle W. R., Nahmias A. J., Harwell R. W., Pauls F. P. Association of antigenic type of Herpesvirus hominis with site of viral recovery. J Immunol. 1967 Nov;99(5):974–980. [PubMed] [Google Scholar]
  4. Goodheart C. R., Plummer G., Waner J. L. Density difference of DNA of human herpes simplex viruses, types I and II. Virology. 1968 Jul;35(3):473–475. doi: 10.1016/0042-6822(68)90225-0. [DOI] [PubMed] [Google Scholar]
  5. HOGGAN M. D., ROIZMAN B. The isolation and properties of a variant of Herpes simplex producing multinucleated giant cells in monolayer cultures in the presence of antibody. Am J Hyg. 1959 Sep;70:208–219. doi: 10.1093/oxfordjournals.aje.a120071. [DOI] [PubMed] [Google Scholar]
  6. ISAACS A. INTERFERON. Adv Virus Res. 1963;10:1–38. [PubMed] [Google Scholar]
  7. Kleger B., Prier J. E. Herpes simplex infection of the female genital tract. II. Association of cytopathic effect in cell culture with site of infection. J Infect Dis. 1969 Sep;120(3):376–378. doi: 10.1093/infdis/120.3.376. [DOI] [PubMed] [Google Scholar]
  8. Lerner A. M., Bailey E. J., Nolan D. C. Complement-requiring neutralizing antibodies in Herpesvirus hominis encephalitis. J Immunol. 1970 Mar;104(3):607–615. [PubMed] [Google Scholar]
  9. Nahmias A. J., Dowdle W. R., Kramer J. H., Luce C. F., Mansour S. C. Antibodies to Herpesvirus hominis types 1 and 2 in the rabbit. J Immunol. 1969 Apr;102(4):956–962. [PubMed] [Google Scholar]
  10. Nolan D. C., Carruthers M. M., Lerner A. M. Herpesvirus hominis encephalitis in Michigan. Report of thirteen cases, including six treated with idoxuridine. N Engl J Med. 1970 Jan 1;282(1):10–13. doi: 10.1056/NEJM197001012820103. [DOI] [PubMed] [Google Scholar]
  11. Plummer G., Waner J. L., Phuangsab A., Goodheart C. R. Type 1 and type 2 herpes simplex viruses: serological and biological differences. J Virol. 1970 Jan;5(1):51–59. doi: 10.1128/jvi.5.1.51-59.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. SCOTT T. F., McLEOD D. L., TOKUMARU T. A biologic comparison of two strains of Herpesvirus hominis. J Immunol. 1961 Jan;86:1–12. [PubMed] [Google Scholar]
  13. Terni M., Roizman B. Variability of herpes simplex virus: isolation of two variants from simultaneous eruptions at different sites. J Infect Dis. 1970 Feb;121(2):212–216. doi: 10.1093/infdis/121.2.212. [DOI] [PubMed] [Google Scholar]
  14. Wentworth B. B., French L. Plaque assay of Herpesvirus hominis on human embryonic fibroblasts. Proc Soc Exp Biol Med. 1969 Jun;131(2):588–592. doi: 10.3181/00379727-131-33932. [DOI] [PubMed] [Google Scholar]
  15. Wheeler C. E., Jr, Briggaman R. A., Henderson R. R. Plaque titration of herpes simplex with antibody-free liquid overlay. Proc Soc Exp Biol Med. 1968 Mar;127(3):814–818. doi: 10.3181/00379727-127-32810. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES